Amino Acid Changes within Conserved Region III of the Herpes Simplex Virus and Human Cytomegalovirus DNA Polymerases Confer Resistance to 4-Oxo-Dihydroquinolines, a Novel Class of Herpesvirus Antiviral Agents
Open Access
- 1 February 2003
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 77 (3) , 1868-1876
- https://doi.org/10.1128/jvi.77.3.1868-1876.2003
Abstract
The 4-oxo-dihydroquinolines (PNU-182171 and PNU-183792) are nonnucleoside inhibitors of herpesvirus polymerases (R. J. Brideau et al., Antiviral Res. 54:19-28, 2002; N. L. Oien et al., Antimicrob. Agents Chemother. 46:724-730, 2002). In cell culture these compounds inhibit herpes simplex virus type 1 (HSV-1), HSV-2, human cytomegalovirus (HCMV), varicella-zoster virus (VZV), and human herpesvirus 8 (HHV-8) replication. HSV-1 and HSV-2 mutants resistant to these drugs were isolated and the resistance mutation was mapped to the DNA polymerase gene. Drug resistance correlated with a point mutation in conserved domain III that resulted in a V823A change in the HSV-1 or the equivalent amino acid in the HSV-2 DNA polymerase. Resistance of HCMV was also found to correlate with amino acid changes in conserved domain III (V823A+V824L). V823 is conserved in the DNA polymerases of six (HSV-1, HSV-2, HCMV, VZV, Epstein-Barr virus, and HHV-8) of the eight human herpesviruses; the HHV-6 and HHV-7 polymerases contain an alanine at this amino acid. In vitro polymerase assays demonstrated that HSV-1, HSV-2, HCMV, VZV, and HHV-8 polymerases were inhibited by PNU-183792, whereas the HHV-6 polymerase was not. Changing this amino acid from valine to alanine in the HSV-1, HCMV, and HHV-8 polymerases alters the polymerase activity so that it is less sensitive to drug inhibition. In contrast, changing the equivalent amino acid in the HHV-6 polymerase from alanine to valine alters polymerase activity so that PNU-183792 inhibits this enzyme. The HSV-1, HSV-2, and HCMV drug-resistant mutants were not altered in their susceptibilities to nucleoside analogs; in fact, some of the mutants were hypersensitive to several of the drugs. These results support a mechanism where PNU-183792 inhibits herpesviruses by interacting with a binding determinant on the viral DNA polymerase that is less important for the binding of nucleoside analogs and deoxynucleoside triphosphates.Keywords
This publication has 31 references indexed in Scilit:
- Inhibition of clinical isolates of human cytomegalovirus and varicella zoster virus by PNU‐183792, a 4‐oxo‐dihydroquinolineJournal of Medical Virology, 2002
- Potent and Selective Inhibition of Human Cytomegalovirus Replication by 1263W94, a Benzimidazole l -Riboside with a Unique Mode of ActionAntimicrobial Agents and Chemotherapy, 2002
- A Novel Nonnucleoside Inhibitor Specifically Targets Cytomegalovirus DNA Maturation via the UL89 and UL56 Gene ProductsJournal of Virology, 2001
- Structure of the Replicating Complex of a Pol α Family DNA PolymeraseCell, 2001
- Summary of the III International Consensus Symposium on Combined Antiviral TherapyAntiviral Research, 1998
- Herpes Simplex VirusesClinical Infectious Diseases, 1998
- Functional analysis of human cytomegalovirus polymerase accessory proteinVirus Research, 1994
- Primary structure of the catalytic subunit of calf thymus DNA polymerase .delta.: sequence similarities with other DNA polymerasesBiochemistry, 1991
- The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapyAntiviral Research, 1991
- Cytopathogenicity, drug susceptibility, and thymidine kinase activity of a retinovirulent herpes simplex virus type 2Journal of Medical Virology, 1990